BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 [PMID: 31966908 DOI: 10.4254/wjh.v11.i12.761] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Savant AP, McColley SA. Cystic fibrosis year in review 2019: Section 1 CFTR modulators. Pediatr Pulmonol 2020;55:3236-42. [PMID: 32833326 DOI: 10.1002/ppul.25039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Konrad J, Eber E, Stadlbauer V. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators. Paediatr Respir Rev 2020:S1526-0542(20)30181-0. [PMID: 33485777 DOI: 10.1016/j.prrv.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Balfour-Lynn IM, King JA. CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev 2020:S1526-0542(20)30081-6. [PMID: 32565113 DOI: 10.1016/j.prrv.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
5 Pozo L, Bello F, Mendez Y, Surani S. Cystic fibrosis-related diabetes: The unmet need. World J Diabetes 2020; 11(6): 213-217 [PMID: 32547695 DOI: 10.4239/wjd.v11.i6.213] [Reference Citation Analysis]
6 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Zarei K, Stroik MR, Gansemer ND, Thurman AL, Ostedgaard LS, Ernst SE, Thornell IM, Powers LS, Pezzulo AA, Meyerholz DK, Stoltz DA. Early pathogenesis of cystic fibrosis gallbladder disease in a porcine model. Lab Invest 2020;100:1388-99. [PMID: 32719544 DOI: 10.1038/s41374-020-0474-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Dana J, Debray D, Beaufrère A, Hillaire S, Fabre M, Reinhold C, Baumert T, Berteloot L, Vilgrain V. Cystic fibrosis-related liver disease: clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies. J Hepatol 2021:S0168-8278(21)02115-2. [PMID: 34678405 DOI: 10.1016/j.jhep.2021.09.042] [Reference Citation Analysis]
9 McBennett K, MacAskill CJ, Keshock E, Mahani MG, Mata J, Towbin AJ, Sankararaman S, Drumm ML, Yu X, Ren CL, Nasr SZ, Kutney K, Flask CA. Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies. J Cyst Fibros 2021:S1569-1993(21)02143-3. [PMID: 34879996 DOI: 10.1016/j.jcf.2021.11.006] [Reference Citation Analysis]
10 Eschenhagen P, Schwarz C. [Many patients with cystic fibrosis have a better quality of life now]. MMW Fortschr Med 2021;163:74-81. [PMID: 33950452 DOI: 10.1007/s15006-021-9804-z] [Reference Citation Analysis]
11 Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep 2021;23:17. [PMID: 34448955 DOI: 10.1007/s11894-021-00817-2] [Reference Citation Analysis]
12 Athwal VS, Scott JA, Fitzpatrick E, Rowland M. Emerging clinical perspectives in cystic fibrosis liver disease. Curr Opin Pulm Med 2021;27:593-9. [PMID: 34482340 DOI: 10.1097/MCP.0000000000000824] [Reference Citation Analysis]